Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

KALETRA Clinical Trials

« Back to Dashboard
First 100 trials shown — repeat this search at ClinicalTrials.gov

Title Status Condition Last Changed FDA link
Comparison of Liquid Kaletra and Low Dose Kaletra Tablets Completed HIV Infections February 5, 2014 NCT00762320
GSK706769/KALETRA Drug-drug Interaction Study Completed Healthy Subjects; Infection, Human Immunodeficiency Virus June 21, 2012 NCT00723775
Lopinavir Capsules to Kaletra or Invirase Tablets Completed HIV Infections July 15, 2011 NCT00438152
KONCERT A Kaletra ONCE Daily Randomised Trial of the Pharmacokinetics, Safety and Efficacy of Twice-daily Versus Once-daily Lopinavir/Ritonavir Tablets Dosed by Weight as Part of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-1 (HIV-1) Infected Children (PENTA 18) Completed Antiretroviral Therapy in HIV-1 Infected Children October 25, 2013 NCT01196195
Drug-drug Interaction Study Between Lopinavir/Ritonavir and Isavuconazole Completed Pharmacokinetics of Isavuconazole; Pharmacokinetics of Lopinavir/Ritonavir; Healthy Volunteers February 20, 2015 NCT01660477
Evaluation of Kaletra Therapy Over the Long-term Completed Human Immunodeficiency Virus August 9, 2011 NCT01083810
Lopinavir/Ritonavir (Kaletra) PK in Children Completed HIV/AIDS Treatment; HIV Infections June 2, 2012 NCT00810108
The Effect of Pregnancy on the Pharmacokinetics of the Kaletra Tablet Completed Pregnancy; HIV May 11, 2011 NCT00766818
Metabolic Effects of Switching Kaletra to Boosted Reyataz Completed HIV Infections March 5, 2010 NCT00413153
Pilot Study of Effect of Kaletra on CD4 Response in HIV Positive (+) Patients With Viral Suppression KIMBO Study Terminated HIV December 17, 2014 NCT00344487
Kaletra Monotherapy in HIV/HCV Co-infected Subjects Completed HIV Infections May 28, 2012 NCT00508222
Drug Use Investigation of Kaletra Completed Human Immunodeficiency Virus January 31, 2012 NCT01076972
Kaletra and Viread in Antiretroviral Naïve Patients Terminated HIV Infections October 9, 2012 NCT00679926
Special Investigation of Kaletra in Pregnant Women Completed Human Immunodeficiency Virus December 9, 2011 NCT01076985
Efficacy and Safety of Kaletra Monotheraphy Compared to Kaletra Based Triple Therapy to Treat HIV in Antiretroviral Naїve Patients Completed HIV Infection April 1, 2008 NCT00234923
Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin Recruiting AIDS; Tuberculosis June 9, 2016 NCT01700790
A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines Completed HIV November 16, 2015 NCT01172535
Raltegravir Kaletra Pharmacokinetics Completed Healthy June 16, 2008 NCT00564772
An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin Completed HIV Infection; Tuberculosis May 15, 2015 NCT00771498
Drug Interaction Study Between Lumefantrine and Lopinavir/Ritonavir Completed HIV Infections December 3, 2010 NCT00619944
Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China Completed HIV-1 Infections July 7, 2011 NCT01074931
Kaletra-isentress Treatment Evaluation Completed HIV Infections November 25, 2014 NCT00700115
Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients Completed Human Immunodeficiency Virus March 14, 2013 NCT00648999
Pilot Simplification Study to Lopinavir/Ritonavir 800/200 mg Monotherapy Regimen Once Daily Recruiting HIV April 19, 2013 NCT01581853
Pharmacokinetics of the Tablet Formulation of Lopinavir/r as Standard and Increased Dosage During Pregnancy Completed HIV Infections; Pregnancy October 25, 2013 NCT00605098
Clinical Study of an Aluvia-based HAART Regimen for Prevention of Mother-to-child HIV Transmission in Africa Completed HIV June 22, 2015 NCT01088516
Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients Completed HIV Infection July 9, 2008 NCT00234910
KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks Completed HIV Infection; Infection, Human Immunodeficiency Virus May 12, 2011 NCT00085943
A Pilot Study of Kaletra and Intelence Tablets in Naive Subjects Recruiting HIV Infections February 12, 2010 NCT01045369
Safety of Lopinavir/Ritonavir (Kaletra) in HIV/HCV Co-infected Subjects vs Baseline Liver Biopsy Metavir Score Completed HIV Infection January 2, 2013 NCT00234975
ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial Completed HIV-1 November 18, 2011 NCT00772902
Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study) Terminated HIV Infections June 5, 2014 NCT01068873
Pharmacokinetic Study of Two Generic co-Formulations of Lopinavir/Ritonavir for HIV Infected Children (SURF) Completed HIV Infections February 24, 2009 NCT00665951
A Comparison Study of Kaletra Soft-Gel Capsules and Kaletra Tablets in an African American Cohort Completed HIV-1; AIDS April 4, 2007 NCT00268827
Drug Interaction Study of Lopinavir/Ritonavir and Gemfibrozil Completed Healthy Volunteers March 13, 2012 NCT00474201
Pharmacokinetic Interactions Between Buprenorphine and Kaletra (Lopinavir/Ritonavir) Completed HIV Infections October 19, 2012 NCT00571961
Lopinavir (LPV) Dose Reduction Completed HIV-1 Infections July 8, 2010 NCT01159275
PK of Efavirenz & Lopinavir Nano-formulations in Healthy Volunteers Recruiting HIV June 30, 2016 NCT02631473
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection Completed Human Immunodeficiency Virus Infection December 12, 2014 NCT01328158
Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected With HIV and TB Recruiting Acquired Immunodeficiency Syndrome; Tuberculosis January 22, 2015 NCT02348177
Kaletra in Combination With Antiretroviral Agents Completed Human Immunodeficiency Virus February 4, 2016 NCT01076179
MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-032)(TERMINATED) Terminated HIV Infection October 1, 2015 NCT00443703
Ritonavir-boosted Lopinavir Monotherapy Completed HIV November 10, 2011 NCT01002898
Induction-maintenance of Lopinavir/r in HIV-infected Subjects Completed HIV Infections September 4, 2015 NCT00159224
Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected Subjects Completed Human Immunodeficiency Virus Infections April 7, 2011 NCT00358917
Trial About Hepatic Security of Antiretroviral Treatment Based on Kaletra Versus Nevirapine in co-Infected HIV/HCV Patients Terminated HIV Infections April 22, 2009 NCT00661349
Study of Lopinavir/ Ritonavir and Lamivudine Versus Standard Therapy in Naïve HIV-1 Infected Subjects. Completed HIV Infection June 8, 2012 NCT01237444
Study on the Effect of Kaletra + Nevirapine as Maintenance Bitherapy Compared to a Triple Therapy Including Kaletra + Analogues in HIV Patients Completed HIV Infections February 19, 2008 NCT00335686
Dose Reduction of Lopinavir in Children Completed HIV Infections April 22, 2009 NCT00887120
Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL) Completed Human Immunodeficiency Virus Infection February 13, 2012 NCT00711009
Safety Study of Lopinavir/Ritonavir With Raltegravir in HIV-infected Patients Completed HIV Infections July 19, 2011 NCT00752037
Surveillance of Kaletra in Korean Patients Completed HIV-1 Infection January 25, 2016 NCT01083173
Treatment of HIV/HCV Coinfection With Peg-IFN and Ribavirin in Patients Receiving ART Monotherapy With Lopinavir/r Completed HIV/HCV Co-infection; HIV Infections March 21, 2013 NCT00866021
Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV Completed HIV Infection June 3, 2010 NCT00244712
Pharmacokinetics of Lopinavir/Ritonavir at Three Different Doses. Completed Acquired Immunodeficiency Syndrome March 2, 2011 NCT00985543
Maintenance Boosted Lopinavir Monotherapy Following Salvage Protease-inhibitor (PI) Based Regimen in HIV With Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) Based Regimen Failure Completed HIV; AIDS; Lopinavir; Treatment Failure May 10, 2013 NCT01189695
Pharmacokinetics of Generic Lopinavir/Ritonavir in Pregnant Women Completed HIV Infections April 3, 2012 NCT00621166
Analysis of Changes in Adipose Tissue of Patients With Lipoatrophy HIV Infection Treated With Nucleoside Thymidine, After Switching to Monotherapy With Lopinavir / Ritonavir Terminated HIV Infections April 5, 2013 NCT01031849
Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy Active, not recruiting HIV Infections February 12, 2010 NCT01049685
Pilot Assessment of Lopinavir/Ritonavir and Maraviroc Terminated HIV Infections; Acquired Immunodeficiency Syndrome June 20, 2015 NCT00981318
A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects Terminated HIV; Tuberculosis October 29, 2010 NCT00743470
Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting Completed HIV-1 Infection August 22, 2013 NCT01772940
Lopinavir/Ritonavir (LPV/r) Tablet in HIV Infected Children Completed HIV-1 Infections March 24, 2015 NCT01139905
Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients Completed HIV Infections June 23, 2014 NCT00946595
GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir Completed Healthy Volunteer February 20, 2012 NCT00867152
Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets) Completed Human Immunodeficiency Virus Infection April 30, 2013 NCT01383005
Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis Completed Primary Biliary Cirrhosis November 30, 2015 NCT01614405
MERS-CoV Infection tReated With A Combination of Lopinavir /Ritonavir and Interferon Beta-1b Not yet recruiting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) July 23, 2016 NCT02845843
Prevention of Lipoatrophy in Patients Treated With Lopinavir/Ritonavir in Monotherapy Versus ZDV + 3TC + ABC Completed HIV Infection; HIV Infections September 11, 2013 NCT00865475
A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment Completed HIV Infections August 23, 2013 NCT00145795
ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naïve HIV-Infected Subjects Completed HIV Infections April 2, 2008 NCT00004578
Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease Terminated Acquired Immune Deficiency Syndrome May 30, 2014 NCT00775606
Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects Completed HIV Infections July 11, 2015 NCT00654147
Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects Completed Human Immunodeficiency Virus Infections February 3, 2012 NCT00262522
Test Albuvirtide in Experienced Patients Recruiting HIV Infections; AIDS February 18, 2015 NCT02369965
Multicountry, Multicenter Post-Marketing Observational Study of Clinical, Biological and Virological Outcomes, Compliance and Tolerability of Kaletra® in Routine Clinical Use Completed HIV-1 Patients October 10, 2011 NCT01379703
High Dose Ritonavir/Lopinavir Liquid Formulation in Salvage Therapy for Protease Inhibitor Resistant HIV Disease Recruiting HIV; AIDS September 18, 2006 NCT00247143
Evaluation of the Public Health Interest of Kaletra: Impact on Resistance to Antiretrovirals (ARVs) Completed HIV Infection December 13, 2011 NCT01103596
Study of Pharmacokinetic Interaction Between Kaletra® (LPV/r) and BILR 355 BS Plus Ritonavir in Healthy Subjects Completed Healthy October 2, 2014 NCT02256826
Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients Completed HIV Infections March 31, 2014 NCT00752856
Pharmacokinetic Study of Two HIV Protease Inhibitors in Patients Terminated HIV Infection February 5, 2009 NCT00420355
GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection Completed HIV Infections September 23, 2011 NCT00105079
Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir) Completed Drug Interactions; Human Immunodeficiency Virus May 6, 2015 NCT01227590
Kaletra Sex/Gender Pharmacokinetics (PK) Study Completed HIV Infections November 8, 2013 NCT00148759
TDM of Generic Lopinavir/Ritonavir 200/50 mg Completed HIV March 24, 2015 NCT00802334
Four-Drug Combination Treatment in Hiv-Infected Subjects Failing Therapy With Antiretroviral Regimens Completed HIV Infections October 5, 2007 NCT00052117
BOOST: Study of Increased Dosage of Lopinavir/Ritonavir (LPV/r) Terminated HIV Infections December 6, 2010 NCT00414284
Study of Adherence Effects and Clinical Outcomes of Kaletra Based HIV Antiviral Therapy Terminated HIV Infection November 19, 2008 NCT00234962
Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. ANRS 135 Primeva Completed HIV Infections July 17, 2013 NCT00424814
Differences in Blood Levels of Lopinavir/Ritonavir in HIV Infected Men and Women Completed HIV Infections December 2, 2015 NCT00102986
Safety and Effectiveness of Lopinavir/Ritonavir in Individuals Who Have Failed Prior HIV Therapy Completed HIV Infections September 29, 2015 NCT00357552
Lopinavir and Ritonavir in Improving Immune Response to Vaccines in Patients With Complete Remission Following A Bone Marrow Transplant for Hodgkin Lymphoma Withdrawn Hodgkin Lymphoma; Stage I Adult Hodgkin Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage IV Adult Hodgkin Lymphoma June 3, 2016 NCT01165645
Post-Exposure Prophylaxis in Health Care Workers Completed Human Immunodeficiency Virus September 26, 2013 NCT01234116
Clinical Study to Evaluate the Efficacy and Safety of Lopinavir/Ritonavir Monotherapy Versus Darunavir/Ritonavir Monotherapies as Simplification Switching Strategies of PI/NNRTI-Triple Therapy Based-Regimens Completed HIV Infections February 12, 2014 NCT00994344
Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma Terminated Brain Tumor; Anaplastic Astrocytoma; Anaplastic Ependymoma; Anaplastic Oligodendroglioma; Brain Stem Glioma; Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Mixed Glioma April 24, 2013 NCT01095094
Study of the 48-Week Virologic and Immunologic Response to Lopinavir/Ritonavir (Kaletra) in HIV Positive Adult Patients Recruiting HIV Infections July 18, 2005 NCT00116636
Pediatric Study for Appropriate Dose of Ritonavir Boosted Lopinavir in Thai HIV-infected Children (PEARL) Completed HIV-infected Children March 23, 2015 NCT01307124
Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding Completed HIV Infections April 11, 2014 NCT00640263
Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals Completed HIV Infections July 7, 2011 NCT00632970
A Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects Completed HIV Infections September 28, 2006 NCT00075231

Source: ClinicalTrials.gov

This preview shows a limited data set. Complete access is available with a Subscription

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.